Kiromic BioPharma, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 20.95 million compared to USD 34.73 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -28.04% |
|
-21.17% | +101.15% |
Jul. 03 | Kiromic BioPharma, Inc. announced that it has received $2 million in funding | CI |
Jun. 20 | Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+101.15% | 2.71M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- KRBP Stock
- News Kiromic BioPharma, Inc.
- Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023